Evidence map›Paper›PMID 36969467›Full record

ArticleACS omega2023

Process Intensification of a Napabucasin Manufacturing Method Utilizing Microflow Chemistry.

Hirotsugu Usutani, Kenji Yamamoto, Kazuki Hashimoto

Full text read
In one paragraph

Article in ACS omega, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Hirotsugu UsutaniTechnology Research & Development Division, Process Research & Development Laboratories, Sumitomo Pharma Co., Ltd., Kasugade-naka 3-1-98, Konohana-ku, Osaka 554-0022, Japan.ORCID https://orcid.org/0000-0002-8744-1348
Kenji YamamotoTechnology Research & Development Division, Process Research & Development Laboratories, Sumitomo Pharma Co., Ltd., Kasugade-naka 3-1-98, Konohana-ku, Osaka 554-0022, Japan.
Kazuki HashimotoTechnology Research & Development Division, Process Research & Development Laboratories, Sumitomo Pharma Co., Ltd., Kasugade-naka 3-1-98, Konohana-ku, Osaka 554-0022, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Microflow chemistry is one of the newest and most efficient technologies used today for the safe and effective production of medicines. In this paper, we show the use of this technology in the development of a manufacturing method for napabucasin, which has potential in the treatment of colorectal and pancreatic cancers. In conventional "batch-type" reactor systems, the generation of side products can be controlled with traditional techniques such as reagent reverse-addition and temperature control. However, there is a limitation to which the yield and purity can be improved by these methods, as both are constrained by the efficiency of heat/mass transfer. Applying microflow chemistry technology alters the parameters of the constraint through the use of precise mixing in a microchannel, which offers increased possibility for improving yields and process intensification of the napabucasin process. Reported herein is a proof-of-concept study for the scale-up production of napabucasin using microflow chemistry techniques for manufacturing at the kilogram scale.

Identifiers

PMID36969467
PMCPMC10034843

What OpenQuestion holds

Textfull text, public
LicenceCC BY
measurements read47
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.